View source for Encainide

==Administration==
*Type: Class IC antiarrhythmic (sodium channel blocker)
*Dosage Forms: Capsules (25mg or 35mg)
*Routes of Administration: PO
*Common Trade Names: Enkaid

==Adult Dosing==
====Sustained Ventricular Tachycardia====
* 25mg PO t.i.d
**May be increased to 35mg PO t.i.d after 3-5 days

==Pediatric Dosing==
*Safety and effectiveness in pediatrics not established

==Special Populations==
===[[Drug pregnancy categories|Pregnancy Rating]]===
*Category B

===Lactation risk===
*Unknown risk to nursing infants

===Renal Dosing===
*Adult: Reduce to single initial daily 25mg dose; increase to 25mg b.i.d after 7 days if needed.
*Pediatric: N/A

===Hepatic Dosing===
*Adult: No adjustments needed, but use caution when increasing dosage
*Pediatric: N/A

==Contraindications==
*Allergy to class/drug
*Preexisting 2nd or 3rd-degree AV block
*Preexisting right bundle branch block w/ left hemiblock
*Presence of cardiogenic shock

==Adverse Reactions==
===Serious===
*Provocation or aggravation of ventricular arrhythmias
*2nd or 3rd-degree AV block
*Sinus bradycardia

===Common===


==Pharmacology==
*Half-life: 
*Metabolism: 
*Excretion: 

==Mechanism of Action==


==Comments==


==See Also==


==References==
<references/>

[[Category:Pharmacology]]